Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Global Markets




The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved patient population.

Leave a Reply

Your email address will not be published. Required fields are marked *